5.10Open5.10Pre Close0 Volume16 Open Interest10.00Strike Price0.00Turnover0.00%IV2.51%PremiumMay 16, 2025Expiry Date4.73Intrinsic Value100Multiplier6DDays to Expiry0.37Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma3.31Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Neurogene Stock Discussion
Neurogene Reports First Quarter 2025 Financial Results and Highlights Recent Updates
Revolutionary Gene Therapy Technology Successfully Controls Rett Syndrome Treatment in Major Study
Neurogene's $312M War Chest Fuels Promising Rett Syndrome Treatment Progress
This Will continue to drive downward. And after you finally sell your position for a loss, they will buy back. Follow the money
📊⚡️📊
NEWS
Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting
NEW YORK--(BUSINESS WIRE)-- Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that initial safety and tolerability data from its ongoing Phase 1/2 gene therapy clinical trial for Rett syndrome will be ...
No comment yet